TBPH · As filed with the SEC
Theravance Biopharma income statement, by quarter
The statement as Theravance Biopharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS · USD, except per-share amounts
| USD, except per-share amounts | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q4 2024 3 months ended Dec 31, 2024 |
|---|---|---|---|---|---|---|
| Revenues: | ||||||
| Total revenues | 20,731,000 | 17,699,000 | — | 19,990,000 | 26,195,000 | — |
| Viatris collaboration agreement | — | — | — | — | 18,695,000 | — |
| Licensing | — | — | — | — | 7,500,000 | — |
| Collaboration Agreement | 20,731,000 | — | — | 19,990,000 | — | — |
| Expenses: | ||||||
| Research and development | 4,712,000 | 5,829,000 | — | 8,112,000 | 10,490,000 | — |
| Selling, general and administrative | 14,176,000 | 17,720,000 | — | 18,333,000 | 18,430,000 | — |
| Restructuring expenses | 4,031,000 | 3,633,000 | — | — | — | — |
| Transaction-related expenses | 6,089,000 | — | — | — | — | — |
| Total expenses | 29,008,000 | 27,182,000 | — | 26,445,000 | 28,920,000 | — |
| Loss from operations | (8,277,000) | (9,483,000) | — | (6,455,000) | (2,725,000) | — |
| Net gain on realized contingent milestone and royalty assets | — | — | — | — | 75,137,000 | — |
| Interest expense (non-cash) | — | — | — | (573,000) | (663,000) | — |
| Interest and other income, net | 3,486,000 | 3,013,000 | — | 4,139,000 | 1,457,000 | — |
| Income (loss) before income taxes | (4,791,000) | (6,470,000) | — | (2,889,000) | 73,206,000 | — |
| Provision for income tax (expense) benefit | (1,107,000) | 1,537,000 | — | 6,504,000 | (18,371,000) | — |
| Net income (loss) | (5,898,000) | (4,933,000) | — | 3,615,000 | 54,835,000 | — |
| Net unrealized gain on available-for-sale investments | — | — | — | 42,000 | (10,000) | — |
| Total comprehensive income (loss) | — | — | — | 3,657,000 | 54,825,000 | — |
| Net income (loss) per share: | ||||||
| Net income (loss) per share - basic (in dollars per share) | (0.11) | (0.10) | — | 0.07 | 1.09 | — |
| Net income (loss) per share - diluted (in dollars per share) | (0.11) | (0.10) | — | 0.07 | 1.08 | — |
| Shares used to compute net income (loss) per share - basic (in shares) | 51,667,000 | 51,279,000 | — | 50,520,000 | 50,177,000 | — |
| Shares used to compute net income (loss) per share - diluted (in shares) | 51,667,000 | 51,279,000 | — | 51,908,000 | 50,726,000 | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.